Good morning :)
Place Order
Add to Watchlist

Epigral Ltd

EPIGRAL

Epigral Ltd

EPIGRAL
MaterialsCommodity Chemicals
SmallcapWith a market cap of ₹9,311 cr, stock is ranked 581
High RiskStock is 3.73x as volatile as Nifty
2,086.151.82% (-38.60)
2,086.151.82% (-38.60)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
MaterialsCommodity Chemicals
SmallcapWith a market cap of ₹9,311 cr, stock is ranked 581
High RiskStock is 3.73x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

MaterialsCommodity Chemicals
SmallcapWith a market cap of ₹9,311 cr, stock is ranked 581
High RiskStock is 3.73x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
31.727.110.22%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
31.173.551.31%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 1 analyst

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Epigral Limited (formerly Meghmani Finechem Limited) is a manufacturer of essential chemicals, primarily focused on the production of chlor alkali and its derivatives, used across various industries.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Loading...

Financial YearFY 2021FY 2022FY 2023FY 2024TTM
Total Revenue830.791,555.052,196.381,935.782,286.72
Raw Materialssubtract386.52759.411,211.761,071.601,640.79
Power & Fuel Costsubtract27.9364.15145.56141.32
Employee Costsubtract41.2651.9968.8581.31
Selling & Administrative Expensessubtract21.3547.8557.0154.12
Operating & Other expensessubtract90.22118.0616.3099.64
Depreciation/Amortizationsubtract73.5485.91108.95123.56126.96
Interest & Other Itemssubtract29.1144.2765.5073.4975.45
Taxes & Other Itemssubtract60.02130.63169.1794.88150.00
EPS24.2760.8485.0247.1470.64
DPS0.000.005.005.005.00
Payout ratio0.000.000.060.110.07

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Jun 7PDF
Apr 28PDF
FY 2023

Annual report

PDF

Investor Presentation

Apr 25PDF
Jan 24PDF
Jan 19PDF
+3 more
FY 2024

Annual report

PDF

Investor Presentation

Aug 16PDF
Aug 5PDF
 

Peers & Comparison

Comparing 3 stocks from 
MaterialsCommodity Chemicals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Epigral Ltd47.547.110.22%
Solar Industries India Ltd116.8328.500.08%
Linde India Ltd132.3316.560.18%
Deepak Nitrite Ltd45.917.720.27%

Price Comparison

Compare EPIGRAL with any stock or ETF
Compare EPIGRAL with any stock or ETF
EPIGRAL
Loading...

Shareholdings

Promoter Holdings Trend

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

No institutional holdings trend are available

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding68.94%3.68%0.13%3.02%24.23%

Mar 2024

Jun 2024

Sep 2024

Oct 2024

Shareholding History

SepDec '23MarJunSepOct1.15%1.18%1.36%1.47%2.09%3.02%

Mutual Funds Holding Trend

No mutual funds holding trends are available

Top 5 Mutual Funds holding Epigral Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
HSBC Focused Fund - Growth - Direct Plan

Growth
0.5032%2.64%2.64%23/38 (+13)
HSBC Flexi Cap Fund - Growth - Direct Plan

Growth
0.4785%0.88%0.88%69/96 (+23)
HSBC Value Fund - Growth - Direct Plan

Growth
0.4527%0.31%0.31%72/78 (+5)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 2, 2024

Final
Final | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Jul 2, 2024

Cash Dividend

Ex DateEx DateJun 20, 2023

Final
Final | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Jun 20, 2023

Cash Dividend

Ex DateEx DateFeb 1, 2023

Interim
Interim | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Feb 1, 2023

News & Opinions
Earnings
Epigral consolidated net profit rises 114.00% in the September 2024 quarter

Net profit of Epigral rose 114.00% to Rs 81.30 crore in the quarter ended September 2024 as against Rs 37.99 crore during the previous quarter ended September 2023. Sales rose 30.93% to Rs 626.06 crore in the quarter ended September 2024 as against Rs 478.15 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales626.06478.15 31 OPM %28.5022.53 - PBDT157.4387.45 80 PBT125.1855.94 124 NP81.3037.99 114 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Board of Epigral approves doubling of capacity at Dahej

The Board of Epigral at its meeting held on 09 November 2024 has approved the expansion of production capacity of Chlorinated Polyvinyl Chloride Resin (CPVC Resin) and Epichlorohydrin at Dahej, Gujarat at an estimated capex of Rs 780 crore. Details: CPVC Resin - Proposed capacity addition 75,000 TPA (existing capacity 75,000 TPA; 65% capacity utilization) Epichlorohydrin - Proposed capacity addition 50,000 TPA (existing capacity 50,000 TPA; 80% capacity utilization) Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Epigral to table results

Epigral will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Epigral allots 15.19 lakh equity shares under QIP issue

Epigral has allotted 15,19,180 equity shares at an issue price of Rs 2093.13 per equity share under QIP issue for a consideration of Rs 333.05 crore. With this allotment, the paid up equity share capital has increased to Rs 43,14,13,380 consisting of 4,31,41,338 equity shares. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Board of Epigral approves fund raising up to Rs 500 cr

The Board of Epigral at its meeting held on 14 August 2024 has approved fund raising up to Rs 500 crore through issue of securities on preferential allotment basis or qualified institutional placement. Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Epigral to convene board meeting

Epigral will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Board of Epigral to consider proposal for fund raising

The Board of Epigral will meet on 14 August 2024 to consider proposal for raising of funds through various options. Powered by Capital Market - Live

4 months agoCapital Market - Live
Spotlight
Epigral hits 52-week high after Q1 PAT soars YoY to Rs 86 cr

Revenue from operations jumped 43% to Rs 651.20 crore in Q1 FY25 from Rs 454.89 crore posted in Q1 FY24. Profit before tax (PBT) soared to Rs 130.96 crore in Q1 FY25 as compared with Rs 47.41 crore in Q1 FY24. EBITDA stood at Rs 176 crore as against Rs 95 crore in Q1FY24, resgitering the growth of 85% YoY. EBIDTA margin stood at 27% in Q1FY25 as compared with 21% in Q1FY24 on account of increase in utilization and volume contribution from new projects commissioned. Volume grew 29% YoY and 14% QoQ. Major growth comes from Derivatives this growth is primarily attributed to efficient utilization of capacities and also volume from new projects commissioned. Revenue contribution from Derivatives & Specialty business rose sharply and stood at 53% in Q1FY25 vs 37% in Q1FY24. In the April to June 2024 quarter, we commissioned CPVC Resin and Compound facility and by the end of current quarter we expect to commission Chlorotoluenes Value Chain facility, both these projects will drive growth for Epigral in FY2025 and FY2026. We are moving in line with our long term vision to become fully integrated complex catering to diversified industries and grow consistently to create value for our stakeholders.' Epigral, formerly known as Meghmani Finechem, is a leading integrated manufacturer of chemicals in India. The company is the first to set up an Epichlorohydrin plant in the country and is also the largest capacity plant of CPVC Resin. Epigral is also India's fourth largest manufacturer of caustic soda, chlorine and hydrogen and a leading manufacturer of caustic potash, chloromethanes and hydrogen peroxide. The scrip hit a 52 week high at Rs 1,720 in today's intra-day session. Powered by Capital Market - Live

4 months agoCapital Market - Live
Earnings
Epigral consolidated net profit rises 172.52% in the June 2024 quarter

Net profit of Epigral rose 172.52% to Rs 85.87 crore in the quarter ended June 2024 as against Rs 31.51 crore during the previous quarter ended June 2023. Sales rose 43.16% to Rs 651.20 crore in the quarter ended June 2024 as against Rs 454.89 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales651.20454.89 43 OPM %27.0720.89 - PBDT164.4178.21 110 PBT130.9647.41 176 NP85.8731.51 173 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Epigral announces board meeting date

Epigral will hold a meeting of the Board of Directors of the Company on 24 July 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live